A single-dose, randomized, open-label, two-treatment, three-period, three-sequence, partial replicate crossover trial to study relative bioavailability study of the grazoprevir/elbasvir fixed-dose combination in healthy subjects

Trial Profile

A single-dose, randomized, open-label, two-treatment, three-period, three-sequence, partial replicate crossover trial to study relative bioavailability study of the grazoprevir/elbasvir fixed-dose combination in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Elbasvir/grazoprevir (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Most Recent Events

    • 20 Apr 2016 New trial record
    • 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top